Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-100217
Filing Date
2024-11-19
Accepted
2024-11-19 17:03:33
Documents
50
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0220796-10q_denali.htm   iXBRL 10-Q 705914
2 CERTIFICATION ea022079601ex31-1_denali.htm EX-31.1 10412
3 CERTIFICATION ea022079601ex31-2_denali.htm EX-31.2 10448
4 CERTIFICATION ea022079601ex32-1_denali.htm EX-32.1 3624
5 CERTIFICATION ea022079601ex32-2_denali.htm EX-32.2 3703
  Complete submission text file 0001213900-24-100217.txt   4917370

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE deca-20240930.xsd EX-101.SCH 38581
7 XBRL CALCULATION FILE deca-20240930_cal.xml EX-101.CAL 17126
8 XBRL DEFINITION FILE deca-20240930_def.xml EX-101.DEF 240344
9 XBRL LABEL FILE deca-20240930_lab.xml EX-101.LAB 356187
10 XBRL PRESENTATION FILE deca-20240930_pre.xml EX-101.PRE 236519
52 EXTRACTED XBRL INSTANCE DOCUMENT ea0220796-10q_denali_htm.xml XML 609129
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41351 | Film No.: 241477115
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)